Driving synthetic biology forward thanks to the adoption of technology allowing a rapid synthesis of DNA and mRNA

In the rapidly evolving scientific landscape today, the elimination of obstacles to progress is more critical than ever. Precision medicine and targeted therapies are very promising but depend on the capacity to produce massive quantities of DNA in the first research and development phases. Innovations such as the first vaccine against synthetic flu and the progress of pharmaceutical products with fewer side effects depend on the progress of synthetic biology. It is crucial to remove the bottlenecks from synthetic biology work flows that have an impact on speed and progress in research and development, increase costs and, ultimately, delay innovation.

The adoption of artificial intelligence models (AI) stimulates a competitive advantage because almost all companies that make organic discovery or drugs use AI tools to design molecules. New progress in synthetic biology allows a rapid, precise and reproducible writing of DNA and mRNA for large -scale biological applications which replace the need to outsource in a supplier, which saves a lot of time and empower the teams to take their innovations internally.

Rationalization of supply chains and acceleration of deadlines

The elimination of the strangulation neck created by service providers and allowing total control of DNA synthesis in a faster, only high quality and fully automated manner, can help considerably accelerate therapeutic discovery. Traditionally, working with an external supplier could take more than 14 days – however, new technologies can reduce the delay within a day and reduce time to 93%results.

A new enzymatic “ digital approach to the biological converter ” of the synthesis of DNA and mRNA allows biotechnological companies to create molecules on site without delay an external service provider, considerably rationalizing the process. Giving researchers the control of precious data that can be used to optimize their AI models for the discovery and development of drugs allows them to quickly generate new constructions overnight for quick tests and a generation of data on demand.

Fuel the discovery of drugs to develop revolutionary therapies

New technologies allow researchers and pharmaceutical companies to design a gene and do it internally overnight, helping to feed their AI engine. The technology is faster, unique of high quality and fully automated, providing data that feeds the discovery of drugs and the ability to develop revolutionary therapies. An example is the optimization of metabolic pathways, which is significantly affected by AI in synthetic biology, because AI models contain massive quantities of genomic data, experimental results and biochemical knowledge. With these data sets, AI can precisely predict the impact of genetic changes on the metabolic functions of a cell – considerably reducing traditional traditional approaches to tests and errors, allowing targeted advice on genes to modify for optimal results.

Giving scientists direct control over the chronologies of the synthesis of DNA and mRNA is a game changer, allowing high fidelity genes and mRNA constructions to be built overnight, on demand and in the laboratory. This accelerates discovery through the development of drugs, antibodies engineering and research on vaccines by removing delays and unlocking faster experimentation.

Conclusion

Researchers from around the world must continue to take advantage of new technologies to overcome current bottlenecks in synthetic biology workflows and advance the discovery of cutting -edge health and technology solutions. These breakthroughs in synthetic biology could help to accelerate the progress of applications, new vaccines against infectious diseases, precision immunotherapy for cancer and antibody therapy for the creation of substitutes for sustainable engineering meat and agricultural products. The expansion area of ​​synthetic biology is very promising to modernize industries that have a direct impact on the health of the population.

Image: Metamorworks, Getty Images

This message appears through the Medcity influencers program. Anyone can publish their point of view on business and innovation in health care on Medcity News through Medcity influencers. Click here to find out how.